Roivant (NASDAQ: ROIV) insider adds to multimillion stock sales

Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) received a notice that Mayukh Sukhatme plans to sell common shares under Rule 144. The planned sale covers 136,942 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $5,029,208.64 as of the notice.

These shares are to be issued via exercise of options under a registered plan on 08/18/2026, with sales on NASDAQ. Roivant had 722,323,000 shares outstanding of this class. Over the past three months, Sukhatme reported several prior sales of Roivant common shares.

Key Figures

Planned shares to be sold: 136,942 shares Aggregate market value of planned sale: $5,029,208.64 Shares outstanding: 722,323,000 shares +4 more

7 metrics

Planned shares to be sold 136,942 shares Common stock to be sold by Mayukh Sukhatme under Rule 144

Aggregate market value of planned sale $5,029,208.64 Aggregate market value of 136,942 shares to be sold

Shares outstanding 722,323,000 shares Shares outstanding of Roivant common stock class referenced

Prior sale 06/25/2026 500,000 shares; $17,051,141.93 Common shares sold by Mayukh Sukhatme on 06/25/2026

Prior sale 06/26/2026 500,000 shares; $17,039,650.00 Common shares sold by Mayukh Sukhatme on 06/26/2026

Prior sale 08/14/2026 243,177 shares; $8,809,767.72 Common shares sold by Mayukh Sukhatme on 08/14/2026

Prior sale 08/17/2026 284,707 shares; $10,320,571.81 Common shares sold by Mayukh Sukhatme on 08/17/2026

Key Terms

Rule 144, Exercise of Options Under a Registered Plan, aggregate market value, Form 144

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Options Under a Registered Plan financial

"Common | 08/18/2026 | Exercise of Options Under a Registered Plan |"

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC ... | 136942 | 5029208.64 |"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

What insider share sale was reported for ROIV in this Form 144?

The filing reports that Mayukh Sukhatme intends to sell 136,942 shares of Roivant Sciences Ltd. common stock. These shares relate to the exercise of options under a registered plan and are expected to be sold on NASDAQ through a broker.

What is the aggregate market value of the ROIV shares planned for sale?

The planned sale by Mayukh Sukhatme covers shares with an aggregate market value of $5,029,208.64. This value corresponds to the 136,942 common shares listed in the notice to be sold under Rule 144 on or about 08/18/2026.

How many ROIV shares are outstanding for the class involved in this filing?

Roivant Sciences Ltd. reports 722,323,000 shares outstanding of the common stock class referenced. This figure provides context for the 136,942 shares that Mayukh Sukhatme plans to sell under Rule 144 via the broker.

What ROIV share sales has Mayukh Sukhatme reported in the past three months?

Over the past three months, Mayukh Sukhatme reported sales of 500,000 shares on 06/25/2026, 500,000 on 06/26/2026, 243,177 on 08/14/2026, and 284,707 on 08/17/2026. Each transaction involved Roivant common stock and disclosed corresponding dollar amounts.

Through which broker will the ROIV shares be sold under this Form 144?

The notice lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker for the planned sale. The firm will handle the sale of 136,942 Roivant common shares on NASDAQ in connection with the Rule 144 transaction.

What is the method of acquisition for the ROIV shares being sold?

The shares to be sold were acquired through the exercise of options under a registered plan. The Form 144 specifies this method of acquisition for the 136,942 common shares that Mayukh Sukhatme plans to sell for cash on 08/18/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 04:31 PM Accepted by SEC EDGAR 08/18/2026 - 04:29 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001750050
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ROIVANT SCIENCES LTD.
SEC File Number	001-40782
Address of Issuer	7th Floor 50 Broadway London UNITED KINGDOM SW1H 0DB
Phone	44 207 400 3347
Name of Person for Whose Account the Securities are To Be Sold	MAYUKH SUKHATME
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	136942	5029208.64	722323000	08/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/18/2026	Exercise of Options Under a Registered Plan	Issuer			136942	08/18/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MAYUKH SUKHATME 7th Floor 50 Broadway London X0 SW1H 0DB	Common	08/17/2026	284707	10320571.81
MAYUKH SUKHATME 7th Floor 50 Broadway London X0 SW1H 0DB	Common	08/14/2026	243177	8809767.72
MAYUKH SUKHATME 7th Floor 50 Broadway London X0 SW1H 0DB	Common	06/26/2026	500000	17039650.00
Mayukh Sukhatme 7th Floor 50 Broadway London X0 SW1H 0DB	Common	06/25/2026	500000	17051141.93

144: Remarks and Signature

Remarks
Date of Notice	08/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Mayukh Sukhatme
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)